SOLIQUA 100/33 is an injectable medicine used along with diet and exercise to improve blood sugar control in adults with type 2 diabetes.
• SOLIQUA 100/33 is not for use with type 1 diabetes or for people with diabetic ketoacidosis
• It is not known if SOLIQUA 100/33 is safe and effective in children under 18 years of age

You are 65 years of age or older and neither you nor your spouse are working

You are receiving Social Security payments because of a disability

You have end-stage renal disease

This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicaid, Medicare, VA, DOD, TRICARE, or similar federal or state programs, including any state pharmaceutical assistance programs. Should you begin receiving prescription benefits from any federal, state, or other government-funded program at any time, you will no longer be eligible to participate in this program.I confirm that the information provided is accurate and complete, as this is necessary for compliance with federal healthcare program laws.††Accept Terms and Conditions to move forward.

Your savings card is already activated and ready for use

Be sure to bring your savings card with you to your retail pharmacy when you pick up your SOLIQUA 100/33 prescription.

If you still have questions or need further assistance with a savings card for SOLIQUA® 100/33 (insulin glargine & lixisenatide injection) 100 Units/mL & 33 mcg/mL, call 855-262-5295 between 8AM and 8PM ET, Monday through Friday (excluding holidays).

I authorize Sanofi and its agents to ask about my experience and share my responses with my healthcare professional.

YesNo

Select healthcare professional

Healthcare professional's last name

City

StateState is required

Confirm you've reviewed the Registration Authorization and click the "Submit" button to complete.

Registration Authorization

By providing my personal information and registering, I authorize Sanofi US, its affiliates, and their contracted service providers (collectively “Sanofi”) to:

Provide me with additional information about diabetes, Sanofi products and health conditions, promotions, services, and to ask my opinion about such information and topics, including through market research and related surveys;

If available and upon my request (either separately or through this registration), enroll me in a support program for which I may be eligible, which may include additional communications as described in the program;

Contact me for follow-up on any adverse event I may report regarding a Sanofi product;

Use my personal information, which may include personal health information, as described herein, and to contact me through periodic or recurring mail, email, phone calls, voice messages, internet-to-phone messages, SMS text messages, and interactive voice recordings using auto-dialers or prerecorded artificial or voice messages. This may include additional email or text messaging terms and conditions that may be provided to me in the future as part of a registration confirmation email or text message;

Combine my personal information with information about me from third parties to better match the communications or materials with my interests;

De-identify my personal information and use it in performing research, education, business analytics, marketing studies or for other commercial purposes; and

Share my personal information within the Sanofi parties above in order to de-identify it for the purposes described above and as needed to provide any services or communications.

I agree to allow Sanofi to use my personal information for the purposes described above. In addition:

I confirm that I am the subscriber for the telephone numbers provided, I possess the mobile phone, and I am the authorized user for the email address;

I agree to contact Sanofi if my phone, mail or email information changes or if I no longer possess the mobile phone;

I understand that I can get help for text messages by texting HELP and I may opt-out of these communications by using one of the options set forth below or by sending STOP in response to the SMS/text. Message and Data Rates May Apply;

I understand that once my health information is provided to Sanofi, Federal privacy laws may not protect it from further disclosures;

I understand that Sanofi agrees to protect my health information by using and disclosing it only for the purposes allowed by me in this Registration Authorization or as otherwise allowed by law, and Sanofi will not sell or rent my information to unauthorized parties or mailing lists;

I understand that I am not required to register or provide my information and it will not impact my ability to get health care, including any Sanofi medications prescribed by my physician; however, it will impact my ability to receive communications, or receive support through a program;

I also understand that if I register, I may opt-out of receiving communications at any time by notifying Sanofi by telephone at 1-800-633-1610, by sending a letter to Sanofi US, 55 Corporate Drive, PO Box 5925, Mailstop 55A-220A, Bridgewater, NJ 08807, or by clicking Unsubscribe

I understand that I may retain a copy of this Registration Authorization by taking a screenshot of this page.

Registration Authorization

Please read and close to return to form.

By providing my personal information and registering, I authorize Sanofi US, its affiliates, and their contracted service providers (collectively “Sanofi”) to:

Provide me with additional information about diabetes, Sanofi products and health conditions, promotions, services, and to ask my opinion about such information and topics, including through market research and related surveys;

If available and upon my request (either separately or through this registration), enroll me in a support program for which I may be eligible, which may include additional communications as described in the program;

Contact me for follow-up on any adverse event I may report regarding a Sanofi product;

Use my personal information, which may include personal health information, as described herein, and to contact me through periodic or recurring mail, email, phone calls, voice messages, internet-to-phone messages, SMS text messages, and interactive voice recordings using auto-dialers or prerecorded artificial or voice messages. This may include additional email or text messaging terms and conditions that may be provided to me in the future as part of a registration confirmation email or text message;

Combine my personal information with information about me from third parties to better match the communications or materials with my interests;

De-identify my personal information and use it in performing research, education, business analytics, marketing studies or for other commercial purposes; and

Share my personal information within the Sanofi parties above in order to de-identify it for the purposes described above and as needed to provide any services or communications.

I agree to allow Sanofi to use my personal information for the purposes described above. In addition:

I confirm that I am the subscriber for the telephone numbers provided, I possess the mobile phone, and I am the authorized user for the email address;

I agree to contact Sanofi if my phone, mail or email information changes or if I no longer possess the mobile phone;

I understand that I can get help for text messages by texting HELP and I may opt-out of these communications by using one of the options set forth below or by sending STOP in response to the SMS/text. Message and Data Rates May Apply;

I understand that once my health information is provided to Sanofi, Federal privacy laws may not protect it from further disclosures;

I understand that Sanofi agrees to protect my health information by using and disclosing it only for the purposes allowed by me in this Registration Authorization or as otherwise allowed by law, and Sanofi will not sell or rent my information to unauthorized parties or mailing lists;

I understand that I am not required to register or provide my information and it will not impact my ability to get health care, including any Sanofi medications prescribed by my physician; however, it will impact my ability to receive communications, or receive support through a program;

I also understand that if I register, I may opt-out of receiving communications at any time by notifying Sanofi by telephone at 1-800-633-1610, by sending a letter to Sanofi US, 55 Corporate Drive, PO Box 5925, Mailstop 55A-220A, Bridgewater, NJ 08807, or by clicking Unsubscribe

I understand that I may retain a copy of this Registration Authorization by taking a screenshot of this page.

Once you have read this in its entirety, please close this window and check the box if you agree to this Registration Authorization and you wish to continue.

I have read and I agree to the Registration Authorization terms†

†Please review the Registration Authorization. Then check the box to provide your consent and press the Submit button again to sign up.†Please check the box to provide your consent and press the Submit button to sign up.

Message

Don't miss out on a $0 CO-PAY! Restrictions apply.*

Answer a few questions to find out if you’re eligible to save on SOLIQUA 100/33.

Your contact info is requested

This will help us deliver more information about SOLIQUA 100/33 and overall diabetes management.

Get started with our COACH Program

Register to receive:

An assessment call to help us provide personalized support

Ongoing one-on-one phone support from your Coach, a registered nurse

Tools and tips to help you work toward your personal diet, exercise, and blood sugar goals

Sanofi US does not review the information contained on this website and/or database for content, accuracy or completeness. Use of and access to this information is subject to the terms, limitations and conditions set by the website and/or database producer. Sanofi US makes no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Sanofi US necessarily endorse such website and/or database.

You are about to leave a Sanofi US website

Sanofi US does not review the information contained in this website and/or database, content, accuracy or completeness. Use of and access to this information is subject to the terms, limitations and conditions set by the website and/or data producer.

Sanofi US makes no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Sanofi US necessarily endorse such website and/or database.

You are about to move to an Unbranded site

You are moving to an Unbranded site

Email to share this information

Share the news about SOLIQUA® 100/33 (insulin glargine & lixisenatide injection) 100 Units/mL & 33 mcg/mL to help someone you know sign up for savings, support, and to get more information.

Recipient's Name*

Recipient's Email Address*

Your Name*

Your Email Address*

Subject

Your friend wants you to know about a diabetes treatment

Send me a copy of this email (optional)

Your email has been sent

Your email has been sent to:

SOLIQUA 100/33 is an injectable prescription medicine that contains 2 diabetes medicines, insulin glargine and lixisenatide, that may improve blood sugar (glucose) control in adults with type 2 diabetes, when used with diet and exercise in people who are not controlled with long-acting (basal) insulin (less than 60 units daily) or lixisenatide.

It has not been studied in people with a history of pancreatitis.

It is not recommended for people who also take lixisenatide or other medicines called GLP-1 receptor agonists.

It is not for use in people with type 1 diabetes, diabetic ketoacidosis, or who have a stomach problem that causes slow emptying (gastroparesis).

It has not been studied together with short-acting insulin.

It is not known if SOLIQUA 100/33 is safe and effective in children under 18 years of age.

What is the most important information I should know about SOLIQUA 100/33?Do not share your SOLIQUA 100/33 pen with other people, even if the needle has been changed.

SOLIQUA 100/33 can cause serious side effects, including inflammation of the pancreas, which may be life-threatening.

Before using SOLIQUA 100/33, tell your doctor if you have had pancreatitis, stones in your gallbladder, or a history of alcoholism. These medical problems may make you more likely to get pancreatitis. Stop taking SOLIQUA 100/33 and call your healthcare provider right away if you have pain in your stomach area (abdomen) that is severe, and will not go away. The pain may be felt in the back area. The pain may happen with or without vomiting.

Who should not use SOLIQUA 100/33?
Do not use SOLIQUA 100/33 if you are having an episode of low blood sugar or if you are allergic to insulin glargine, lixisenatide, or any of the ingredients in SOLIQUA 100/33.

Tell your healthcare provider about all your medical conditions, including if you:

have or have had problems with your pancreas, your kidneys, or your liver, stones in your gallbladder, or a history of alcoholism.

have heart failure or other heart problems. If you have heart failure, it may get worse while you take TZDs (thiazolidinediones).

have severe problems with your stomach, such as slowed emptying of your stomach or problems digesting food.

are pregnant or breastfeeding or plan to become pregnant or to breastfeed. It is not known if SOLIQUA 100/33 will harm your unborn baby or pass into your breast milk.

Tell your healthcare provider about all the medicines you take, including all prescription and over-the-counter medicines, vitamins, and herbal supplements. SOLIQUA 100/33 may affect the way some medicines work. Before using SOLIQUA 100/33, talk to your healthcare provider about low blood sugar and how to manage it.

How should I use SOLIQUA 100/33?

Do not change your dose without first talking to your healthcare provider.

Check the pen label each time you inject to make sure you are using the correct medicine.

Do not take more than 60 units of SOLIQUA 100/33 each day. Do not take SOLIQUA 100/33 with other GLP-1 receptor agonists.

Only use SOLIQUA 100/33 that is clear and colorless to almost colorless. If you see small particles, return it to your pharmacy for replacement.

Do not remove SOLIQUA 100/33 from the pen with a syringe.

Do not re-use or share needles with other people. You may give other people a serious infection, or get a serious infection from them.

Check your blood sugar levels. Ask your healthcare provider what your blood sugar should be and when you should check.

SOLIQUA 100/33 may cause serious side effects, including:

Serious allergic reactions. Stop taking SOLIQUA 100/33 and get help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, and very rapid heartbeat.

Kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may worsen kidney problems.

Low potassium in your blood (hypokalemia).

Heart failure. Taking certain diabetes pills called TZDs (thiazolidinediones) with SOLIQUA 100/33 may cause heart failure in some people. This can happen even if you have never had heart failure or heart problems before. If you already have heart failure, it may get worse while you take TZDs with SOLIQUA 100/33. Tell your healthcare provider if you have any new or worse symptoms of heart failure, including shortness of breath, swelling of your ankles or feet, sudden weight gain.

The most common side effects of SOLIQUA 100/33 may include low blood sugar (hypoglycemia), stuffy or runny nose and sore throat, upper respiratory tract infection, headache, allergic reactions, nausea, and diarrhea. Nausea and diarrhea usually happen more often when you start using SOLIQUA 100/33.

What is the most important information I should know about SOLIQUA 100/33?Do not share your SOLIQUA 100/33 pen with other people, even if the needle has been changed.

SOLIQUA 100/33 can cause serious side effects, including inflammation of the pancreas, which may be life-threatening.

Before using SOLIQUA 100/33, tell your doctor if you have had pancreatitis, stones in your gallbladder, or a history of alcoholism. These medical problems may make you more likely to get pancreatitis. Stop taking SOLIQUA 100/33 and call your healthcare provider right away if you have pain in your stomach area (abdomen) that is severe, and will not go away. The pain may be felt in the back area. The pain may happen with or without vomiting.

Who should not use SOLIQUA 100/33?
Do not use SOLIQUA 100/33 if you are having an episode of low blood sugar or if you are allergic to insulin glargine, lixisenatide, or any of the ingredients in SOLIQUA 100/33.

Tell your healthcare provider about all your medical conditions, including if you:

have or have had problems with your pancreas, your kidneys, or your liver, stones in your gallbladder, or a history of alcoholism.

have heart failure or other heart problems. If you have heart failure, it may get worse while you take TZDs (thiazolidinediones).

have severe problems with your stomach, such as slowed emptying of your stomach or problems digesting food.

are pregnant or breastfeeding or plan to become pregnant or to breastfeed. It is not known if SOLIQUA 100/33 will harm your unborn baby or pass into your breast milk.

Tell your healthcare provider about all the medicines you take, including all prescription and over-the-counter medicines, vitamins, and herbal supplements. SOLIQUA 100/33 may affect the way some medicines work. Before using SOLIQUA 100/33, talk to your healthcare provider about low blood sugar and how to manage it.

How should I use SOLIQUA 100/33?

Do not change your dose without first talking to your healthcare provider.

Check the pen label each time you inject to make sure you are using the correct medicine.

Do not take more than 60 units of SOLIQUA 100/33 each day. Do not take SOLIQUA 100/33 with other GLP-1 receptor agonists.

Only use SOLIQUA 100/33 that is clear and colorless to almost colorless. If you see small particles, return it to your pharmacy for replacement.

Do not remove SOLIQUA 100/33 from the pen with a syringe.

Do not re-use or share needles with other people. You may give other people a serious infection, or get a serious infection from them.

Check your blood sugar levels. Ask your healthcare provider what your blood sugar should be and when you should check.

SOLIQUA 100/33 may cause serious side effects, including:

Serious allergic reactions. Stop taking SOLIQUA 100/33 and get help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, and very rapid heartbeat.

Kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may worsen kidney problems.

Low potassium in your blood (hypokalemia).

Heart failure. Taking certain diabetes pills called TZDs (thiazolidinediones) with SOLIQUA 100/33 may cause heart failure in some people. This can happen even if you have never had heart failure or heart problems before. If you already have heart failure, it may get worse while you take TZDs with SOLIQUA 100/33. Tell your healthcare provider if you have any new or worse symptoms of heart failure, including shortness of breath, swelling of your ankles or feet, sudden weight gain.

The most common side effects of SOLIQUA 100/33 may include low blood sugar (hypoglycemia), stuffy or runny nose and sore throat, upper respiratory tract infection, headache, allergic reactions, nausea, and diarrhea. Nausea and diarrhea usually happen more often when you start using SOLIQUA 100/33.

If you are a patient experiencing problems with a Sanofi U.S. product, please contact Sanofi U.S. at 1-800-633-1610

The health information contained herein is provided for general educational purposes only. Your healthcare professional is the single best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.

*This offer is for commercially insured patients and is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, or TRICARE, or similar federal or state programs including any state pharmaceutical programs. Void where prohibited by law. Savings card carries maximum savings of $800 off per pack for the duration of the program. Savings may vary depending on patient’s out-of-pocket costs. Upon registration, patient receives all program details. Sanofi US reserves the right to rescind, revoke, or amend the program without notice.